Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Regulatory News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Jul 2023 10:56

RNS Number : 8235G
MGC Pharmaceuticals Limited
21 July 2023
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

AU000000MXC6

Issuer Name

MGC Pharmaceuticals Limited

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Miton UK MicroCap Trust plc

City of registered office (if applicable)

London

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Name

City of registered office

Country of registered office

BNY (OCS) Nominees Limited

London

England

5. Date on which the threshold was crossed or reached

14-Jul-2023

6. Date on which Issuer notified

18-Jul-2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

4.526895

0.000000

4.526895

176203028

Position of previous notification (if applicable)

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

AU000000MXC6

176203028

4.526895

Sub Total 8.A

176203028

4.526895%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 

Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

 

12. Date of Completion

18/07/2023

13. Place Of Completion

Exeter, UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUAVKROSUBURR
Date   Source Headline
28th Sep 20224:35 pmRNSPrice Monitoring Extension
28th Sep 20227:00 amRNSContravention of the TGA Advertising Code
23rd Sep 20227:00 amRNSUS$550,000 funding received under Mercer Facility
21st Sep 20227:00 amRNSCimetrA™ Dose Finding Study Interim Results
8th Sep 202212:47 pmRNSWebsite / Social Media update
6th Sep 202211:30 amRNSDispatch of General Meeting Documents
1st Sep 20227:00 amRNSPreliminary Financial Report for 30 June 2022
25th Aug 20227:00 amRNSFinal Payment for Malta GMP Manufacturing Plant
17th Aug 20227:00 amRNSAMC Holdings, Inc. places US$1M ArtemiC™ order
15th Aug 20227:00 amRNSCannEpil® Clinical Study on Driving Performance
11th Aug 202211:05 amRNSSecond Price Monitoring Extn
11th Aug 202211:00 amRNSPrice Monitoring Extension
8th Aug 202210:30 amRNSUpdated Investor Presentation
3rd Aug 20227:00 amRNSFirst Tranche of Mercer Street Funding Received
29th Jul 20227:00 amRNSUS$10m Financing Agreement with Mercer Street
28th Jul 20227:45 amRNSPurchase of Strategic 40% Stake in AI Software
25th Jul 20227:00 amRNSJune Quarterly Activities Report and Cash Flow
19th Jul 20227:00 amRNSChief Commercial Officer Appointment
14th Jul 20224:41 pmRNSSecond Price Monitoring Extn
14th Jul 20224:36 pmRNSPrice Monitoring Extension
14th Jul 20222:05 pmRNSSecond Price Monitoring Extn
14th Jul 20222:00 pmRNSPrice Monitoring Extension
14th Jul 202211:05 amRNSSecond Price Monitoring Extn
14th Jul 202211:00 amRNSPrice Monitoring Extension
14th Jul 20229:05 amRNSSecond Price Monitoring Extn
14th Jul 20229:00 amRNSPrice Monitoring Extension
14th Jul 20227:16 amRNSClinical Study results - patients with Long COVID
8th Jul 20227:00 amRNSApproval Granted for CimetrA Dose Finding Study
6th Jul 20228:00 amRNSLaunch of ZAM - Medical data App
27th Jun 20227:00 amRNSCimetrATM Pre-clinical Trial Progress Report
24th Jun 20227:00 amRNSUSA Market Update: CimetrA Clinical Trial Progress
16th Jun 20227:00 amRNSSuccessful Glioblastoma Pre-clinical Trial Results
6th Jun 20227:00 amRNSCogniCann© Phase II Clinical Trial Results
27th May 20221:08 pmRNSCompliance Filing of UK subsidiary FY21 Accounts
23rd May 202210:43 amRNSApplication for Admission to Trading
20th May 20227:00 amRNSAcademic Paper on Effect of ArtemiC™ Published
18th May 202212:06 pmRNSDirector/PDMR Shareholding
10th May 20227:01 amRNSCannEpil® Drug Delivery System Patent Approval
9th May 202212:28 pmRNSDirector/PDMR Shareholding
6th May 20223:08 pmRNSReplacement: Director/PDMR Shareholding
5th May 202211:10 amRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSPartnership with HempStreet
29th Apr 20224:41 pmRNSSecond Price Monitoring Extn
29th Apr 20224:35 pmRNSPrice Monitoring Extension
29th Apr 202210:03 amRNSMarch Quarterly Activities Report and Cash Flow
26th Apr 20227:00 amRNSAppointment of new Chief Financial Officer
25th Apr 202211:08 amRNSApplication for Admission to Trading
21st Apr 20227:00 amRNSCimetrA™ Patent Approved by European IP Office
12th Apr 20228:36 amRNSPerformance Rights and Change of CFO
7th Apr 202210:35 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.